Waldenström macroglobulinaemia

Rafael Fonseca, Suzanne Hayman

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Over time, Waldenström macroglobulinaemia (WM) has evolved conceptually from a clinical syndrome to a distinct clinicopathological entity. Progress is being made in standardization of the disease definition and treatment response criteria, although nosologic controversies persist. According to the Second International Workshop on WM, the disease is defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in the bone marrow, with an associated immunoglobulin (Ig) M paraprotein. Disease symptoms are often divided into those related to tumour infiltration and those related to the rheological effects of the monoclonal IgM. As with other low-grade lymphomas, asymptomatic patients are observed only, with treatment reserved for symptomatic patients. There is no standard treatment for WM and choices include rituximab, alkylating agents, purine nucleoside analogues, alone or in combination, as well as autologous peripheral blood stem cell transplant in eligible patients. Novel treatments, such as bortezomib, oblimersen sodium, perifosine and others are being evaluated.

Original languageEnglish (US)
Pages (from-to)700-720
Number of pages21
JournalBritish Journal of Haematology
Volume138
Issue number6
DOIs
StatePublished - Sep 2007

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
Paraproteins
Purine Nucleosides
Alkylating Agents
Therapeutics
Non-Hodgkin's Lymphoma
Neoplasms
B-Lymphocytes
Bone Marrow
Transplants
Education

Keywords

  • Lymphoplasmacytic lymphoma
  • Waldenström macroglobulinaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Waldenström macroglobulinaemia. / Fonseca, Rafael; Hayman, Suzanne.

In: British Journal of Haematology, Vol. 138, No. 6, 09.2007, p. 700-720.

Research output: Contribution to journalArticle

Fonseca, Rafael ; Hayman, Suzanne. / Waldenström macroglobulinaemia. In: British Journal of Haematology. 2007 ; Vol. 138, No. 6. pp. 700-720.
@article{766cd2a7ccaa4493bc0b78b6d582113b,
title = "Waldenstr{\"o}m macroglobulinaemia",
abstract = "Over time, Waldenstr{\"o}m macroglobulinaemia (WM) has evolved conceptually from a clinical syndrome to a distinct clinicopathological entity. Progress is being made in standardization of the disease definition and treatment response criteria, although nosologic controversies persist. According to the Second International Workshop on WM, the disease is defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in the bone marrow, with an associated immunoglobulin (Ig) M paraprotein. Disease symptoms are often divided into those related to tumour infiltration and those related to the rheological effects of the monoclonal IgM. As with other low-grade lymphomas, asymptomatic patients are observed only, with treatment reserved for symptomatic patients. There is no standard treatment for WM and choices include rituximab, alkylating agents, purine nucleoside analogues, alone or in combination, as well as autologous peripheral blood stem cell transplant in eligible patients. Novel treatments, such as bortezomib, oblimersen sodium, perifosine and others are being evaluated.",
keywords = "Lymphoplasmacytic lymphoma, Waldenstr{\"o}m macroglobulinaemia",
author = "Rafael Fonseca and Suzanne Hayman",
year = "2007",
month = "9",
doi = "10.1111/j.1365-2141.2007.06724.x",
language = "English (US)",
volume = "138",
pages = "700--720",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Waldenström macroglobulinaemia

AU - Fonseca, Rafael

AU - Hayman, Suzanne

PY - 2007/9

Y1 - 2007/9

N2 - Over time, Waldenström macroglobulinaemia (WM) has evolved conceptually from a clinical syndrome to a distinct clinicopathological entity. Progress is being made in standardization of the disease definition and treatment response criteria, although nosologic controversies persist. According to the Second International Workshop on WM, the disease is defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in the bone marrow, with an associated immunoglobulin (Ig) M paraprotein. Disease symptoms are often divided into those related to tumour infiltration and those related to the rheological effects of the monoclonal IgM. As with other low-grade lymphomas, asymptomatic patients are observed only, with treatment reserved for symptomatic patients. There is no standard treatment for WM and choices include rituximab, alkylating agents, purine nucleoside analogues, alone or in combination, as well as autologous peripheral blood stem cell transplant in eligible patients. Novel treatments, such as bortezomib, oblimersen sodium, perifosine and others are being evaluated.

AB - Over time, Waldenström macroglobulinaemia (WM) has evolved conceptually from a clinical syndrome to a distinct clinicopathological entity. Progress is being made in standardization of the disease definition and treatment response criteria, although nosologic controversies persist. According to the Second International Workshop on WM, the disease is defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in the bone marrow, with an associated immunoglobulin (Ig) M paraprotein. Disease symptoms are often divided into those related to tumour infiltration and those related to the rheological effects of the monoclonal IgM. As with other low-grade lymphomas, asymptomatic patients are observed only, with treatment reserved for symptomatic patients. There is no standard treatment for WM and choices include rituximab, alkylating agents, purine nucleoside analogues, alone or in combination, as well as autologous peripheral blood stem cell transplant in eligible patients. Novel treatments, such as bortezomib, oblimersen sodium, perifosine and others are being evaluated.

KW - Lymphoplasmacytic lymphoma

KW - Waldenström macroglobulinaemia

UR - http://www.scopus.com/inward/record.url?scp=34548147654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548147654&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06724.x

DO - 10.1111/j.1365-2141.2007.06724.x

M3 - Article

C2 - 17672883

AN - SCOPUS:34548147654

VL - 138

SP - 700

EP - 720

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -